This story has been updated from a previous version, which inadvertently omitted Aeris Capital as an investor.

NEW YORK (GenomeWeb News) – Tethys Bioscience has closed $25 million in Series D financing, which it plans to use to expand commercialization of its PreDx Diabetes Risk Score test.

The funding round was led by Aeris Capital, and included current investors MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield and Byers, and Intel Capital; and one new investor, Wasatch Advisors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.